Traynor Capital Management, Inc. Galectin Therapeutics Inc Transaction History
Traynor Capital Management, Inc.
- $1.17 Billion
- Q1 2025
A detailed history of Traynor Capital Management, Inc. transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Traynor Capital Management, Inc. holds 76,920 shares of GALT stock, worth $286,911. This represents 0.01% of its overall portfolio holdings.
Number of Shares
76,920
Previous 55,670
38.17%
Holding current value
$286,911
Previous $66,000
40.91%
% of portfolio
0.01%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding GALT
# of Institutions
99Shares Held
9.9MCall Options Held
587KPut Options Held
2.02M-
Vanguard Group Inc Valley Forge, PA2.19MShares$8.18 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$5.83 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.22MShares$4.56 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA853KShares$3.18 Million0.0% of portfolio
-
Geneos Wealth Management Inc.423KShares$1.58 Million0.02% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $222M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...